<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3950">
  <stage>Registered</stage>
  <submitdate>25/03/2013</submitdate>
  <approvaldate>25/03/2013</approvaldate>
  <nctid>NCT01822314</nctid>
  <trial_identification>
    <studytitle>Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer</studytitle>
    <scientifictitle>Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer " ETNA (Evaluating Treatment With Neoadjuvant Abraxane)</scientifictitle>
    <utrn />
    <trialacronym>ETNA</trialacronym>
    <secondaryid>2012-003481-41</secondaryid>
    <secondaryid>FM-12-B01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Abraxane
Treatment: drugs - Paclitaxel

Active Comparator: Paclitaxel - Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.
AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles

Experimental: Abraxane - Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.
AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles


Treatment: drugs: Abraxane
Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles

Treatment: drugs: Paclitaxel
Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pathologic Complete Response (pCR) - To compare the rate of pathologic Complete Response (pCR, absence of invasive disease in breast and nodes (ypT0/ypTis, ypN0)) for abraxane (AbraxaneÂ®, abraxane) vs paclitaxel.</outcome>
      <timepoint>At the time of surgery: 40 months after the randomization of the first patient</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>clinical Overall Response (cOR) - To compare the rate of clinical overall response (cOR) after the first 4 cycles of abraxane vs paclitaxel and to compare the rate of cOR after the entire preoperative chemotherapy (i.e. before surgery) in the study arms of abraxane vs paclitaxel</outcome>
      <timepoint>At the time of surgery: 40 months after the randomization of the first patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival (EFS) - To compare the Event Free Survival (EFS, i.e. disease progression while on primary therapy or disease recurrence after surgery) in the study arms of abraxane vs paclitaxel</outcome>
      <timepoint>5 years after the first patient in and 10 years after randomization of last patient in</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distant Event Free Survival (DEFS) - The distant event free survival (DEFS) is defined as the time from randomization to the first date of distant metastasis while on primary therapy or distant recurrence after surgery or death due to any cause. Patients who terminate the study without evidence of any of the above events will be censored at the date of their last follow-up tumor assessment</outcome>
      <timepoint>5 years after the first patient in and 10 years after randomization of last patient in</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Local Event Free Survival - The local event free survival (LEFS) is defined as the time from randomization to the first date of local progression while on primary therapy or local recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS</outcome>
      <timepoint>5 years after the first patient in and 10 years after randomization of last patient in</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Regional Event Free Survival - The regional event free survival (REFS) is defined as the time from randomization to the first date of regional progression while on primary therapy or regional recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS.</outcome>
      <timepoint>5 years after the first patient in and 10 years after randomization of last patient in</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - The overall survival (OS) is defined as the time from randomization to the date of death. Patients alive at the end of study will be censored at their last contact date.</outcome>
      <timepoint>13 years from the date of first patient in</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability - Patients will be assessed for adverse events by clinical examination, questioning for symptoms of toxicity, laboratory assessments, vital signs, ECG and LVEF.
Neurological toxicity and other toxicities will be assessed throughout the study according the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0.</outcome>
      <timepoint>Each participant will be followed for the duration of treatment period, approximately 9 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female patients aged 18 years or older

          -  Histologically confirmed invasive unilateral breast cancer

          -  HER2-negative disease

          -  Known hormone receptor status (estrogen receptor [ER], progesterone receptor [PgR]),
             tumor grade and, if institutional standard permits, known Ki67 value

          -  Available paraffin-embedded tumor block taken at diagnostic biopsy for central
             confirmation of HER2 eligibility, hormone receptor status, Ki67 value and biomarker
             evaluation is mandatory

          -  One of the following clinical stages:

          -  T2, T3, T4 disease, triple negative (HER2, ER, PgR)

          -  T2, T3, T4 disease, ER or PgR positive and moderately differentiated or poorly
             differentiated tumor grade (G II-III)

          -  ECOG performance status 0 or 1

          -  Written informed consent to participate in the trial (approved by the Institutional
             Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study
             specific screening procedures

          -  Willing and able to comply with the protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Synchronous contralateral breast cancer or presence of metastatic disease (M1).
             Exception: contralateral insitu ductal cancer

          -  Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine needle
             aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not
             recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with
             clinically negative axillary nodes is permitted

          -  Pregnant or lactating women.

          -  Women with childbearing potential unless (1) surgically sterile or (2) using adequate
             measures of contraception, for example abstinence, an intra-uterine device, or double
             barrier method of contraception

          -  Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal
             therapy for the currently diagnosed breast cancer prior to study entry

          -  Previous investigational treatment for any condition within 4 weeks of randomization
             date

          -  Patients on therapy with a strong CYP3A4 inhibitor and on therapy with Warfarin
             (Coumadin)

          -  Previous or concomitant malignancy of any other type that could affect compliance with
             the protocol or interpretation of results. Patients with curatively treated basal cell
             carcinoma of the skin or in situ cervix cancer are generally eligible.

          -  Pre-existing motor or sensory neuropathy of grade &gt; 1 for any reason

          -  Patients with a history of hypersensitivity due to drugs containing polyoxyethylene
             castor oil (Cremophor EL) (e.g., ciclosporin), or hardened castor oil (e.g., vitamin
             preparations for injection, etc.)

          -  Other serious illness or medical condition including: history of documented congestive
             cardiac failure; angina pectoris requiring anti-anginal medication; evidence of
             transmural infarction on ECG; poorly controlled hypertension (e.g. systolic &gt;180 mm Hg
             or diastolic &gt;100 mm Hg; however, patients with hypertension which is well controlled
             on medication are eligible); clinically significant valvular heart disease; high-risk
             uncontrolled arrhythmias

          -  Patients with a history of uncontrolled seizures, central nervous system disorders or
             psychiatric disability judged by the investigator to be clinically significant and
             precluding informed consent or adversely affecting compliance with study drugs

          -  Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes
             mellitus

          -  Hematology and biochemistry tests within normla limits

          -  Baseline left ventricular ejection fraction (LVEF) &lt; 50% by echocardiography or
             multi-gated scintigraphic scan (MUGA)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>632</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2025</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Peter McCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Peter MacCallum Cancer Centre Department of Surgical Oncology - East Melbourne</hospital>
    <hospital>Eastern Health Breast Cancer Research - Maroondah Breast Clinic - Ringwood East</hospital>
    <hospital>Eastern Health Breast Cancer Research Maroondah Breast Clinic - Ringwood East</hospital>
    <hospital>Mount Hospital - Breast Clinical Trials Unit - Perth</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>500 - Adelaide</postcode>
    <postcode>8006 - East Melbourne</postcode>
    <postcode>8600 - East Melbourne</postcode>
    <postcode>3135 - Ringwood East</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Augsburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¶ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Speyer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>GE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MB</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PD</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PV</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>UD</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>VI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Aragon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Tenerife</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A CoruÃ±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Caceres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>CÃ³rdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Donostia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Lleida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Murcia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San SebastiÃ¡n</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Toledo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Ãvila</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Fondazione Michelangelo</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel
      followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or
      Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared with neoadjuvant weekly solvent-based
      paclitaxel followed by AC or EC or FEC in terms of rate of pathological complete remissions
      at surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01822314</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Luca Gianni, MD</name>
      <address>San Raffaele Hospital, Milan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>